News | Radiation Therapy | August 22, 2019

Surging Demand for Image-guided, Stereotactic Radiation Therapy Driving Fiducial Marker Growth

New market report projects worldwide revenue for fiducial markers to pass $100 million by end of 2019

Surging Demand for Image-guided, Stereotactic Radiation Therapy Driving Fiducial Marker Growth

August 22, 2019 — As fiducial markers gain traction in parallel to rising incidences of various cancer affecting lung, prostate, abdomen and kidney, the growth potential of the fiducial markers market is set to witness a considerable rise. Total worldwide sales are anticipated to surpass $100 million by the end of 2019, according to a new study by Fact.MR, registering a significant upswing from $93.9 million in 2018.

The escalating demand for fiducial markers can be accredited to:

As per the study, the adoption of fiducial markers for prostate cancer has been seeing a persistent increase, driven by their ability to aid in seamless target precision. Thus, rising adoption of fiducial markers as an effective tool for use in case of radiation treatment is fostering its popularity.

Use of fiducial markers for prostate cancer is on a steep rise by virtue of its effectiveness in individualizing patient care in advance detection, diagnosis and treatment. Furthermore, adoption of fiducial markers to address rising incidences of breast cancer is also proliferating according to the study, wherein markers are implanted in the target area to mitigate the risk of cancer recurrence.

According to the study, pure gold fiducial markers will outsell all other product types in 2019, with an estimated valuation worth $60 million by the end of 2019. Greater reliability and superior stability are the prime factors responsible for escalating demand for pure gold fiducial markers. Another key factor fueling their growth in the global market is the ability of pure gold fiducial markers to provide high-quality resolution.

While pure gold fiducial markers continue to be profitable, demand for metal-based fiducial markers is also foreseen to scale new heights, owing to their ability to provide superior accuracy in target delivery of radiation. Among all end-users — including hospitals, radiotherapy centers and cancer research centers — sales of fiducial markers are expected to witness a notable uptick in the radiotherapy centers with an anticipated valuation surpassing $39 million this year. According to Fact.MR, radiotherapy centers will look to use the markers to treat various forms of cancer or malignant tumors.

According to the report, North America continues to show significant opportunities for the manufacturers of fiducial markers, with the U.S. leading global demand. The fiducial markers market landscape shows a monopoly of leading players with established brand images and significant product portfolios. Diversification and expansion of existing product lines with new additions remain the key focus areas of the key players.

 The report states that leading players in the fiducial markers market are also investing in extensive research and development to foster seamless product development. Expansion of the customer base through product marketing via online portals is another significant approach adopted by the well-established players in the fiducial markers market.

The report presents actionable insights and opportunity assessment in the fiducial markers market for the forecast period of 2018- 2028. The report predicts market expansion at a compound annual growth rate (CAGR) of over 9 percent through 2028.

Access the full report here.

For more information: www.factmr.com

Related Content

Members of Congress from both sides of the aisle issued a series of oversight letters to the Centers for Medicare and Medicaid Services (CMS) in recent months to urge the Agency to adjust its proposed radiation oncology advanced alternative payment model (RO Model)

Image by whitfieldink from Pixabay

News | Radiation Oncology | November 13, 2019
November 13, 2019 — Members of Congress from both sides of the aisle issued a series of oversight letters to the...
Bladder Abdomen Pelvis image with DLCExpert
News | Artificial Intelligence | November 07, 2019
November 7, 2019 — Mirada Medical, a global leader in...
Liver cancer tumor scanning using an MRI
News | Proton Therapy | November 04, 2019
November 4, 2019 – Two new studies support and inform the use of proton radiation therapy to treat patients with hepa
Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Feature | ASTRO | October 30, 2019 | By Greg Freiherr
At the American Society for Radiation Oncology’s (ASTRO) 2019 a
Advanced Radiation Therapy Upgrades AccuBoost Digital Brachytherapy Platform
News | Brachytherapy Systems, Women's Healthcare | October 23, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago, Advanced Radiation...
MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment
News | Treatment Planning | October 18, 2019
The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an...
GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane...